Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM. Steenbruggen TG, et al. Among authors: basu a. Breast Cancer Res. 2023 Oct 4;25(1):117. doi: 10.1186/s13058-023-01717-1. Breast Cancer Res. 2023. PMID: 37794508 Free PMC article.
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A. Magbanua MJM, et al. Among authors: basu a. Breast Cancer Res Treat. 2023 Apr;198(2):383-390. doi: 10.1007/s10549-022-06803-0. Epub 2023 Jan 23. Breast Cancer Res Treat. 2023. PMID: 36689092 Free PMC article.
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine.
Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Duckett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ. Basu A, et al. Cancer Immunol Res. 2022 Jan;10(1):108-125. doi: 10.1158/2326-6066.CIR-21-0454. Epub 2021 Nov 16. Cancer Immunol Res. 2022. PMID: 34785506 Free PMC article.
Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Ramamoorthi G, et al. Among authors: basu a. J Immunother Cancer. 2022 Jun;10(6):e004841. doi: 10.1136/jitc-2022-004841. J Immunother Cancer. 2022. PMID: 35710296 Free PMC article.
Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ. Kodumudi KN, et al. Among authors: basu a. Front Immunol. 2019 Aug 14;10:1939. doi: 10.3389/fimmu.2019.01939. eCollection 2019. Front Immunol. 2019. PMID: 31475002 Free PMC article.
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Jia Y, et al. Among authors: basu a. Mol Ther. 2021 Apr 7;29(4):1541-1556. doi: 10.1016/j.ymthe.2020.12.037. Epub 2021 Jan 5. Mol Ther. 2021. PMID: 33412308 Free PMC article.
Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ. Rosemblit C, et al. Among authors: basu a. Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796172 Free PMC article.
3,007 results